Neuland Laboratories Limited vs Sun Pharmaceutical Industries Limited

A side-by-side comparison of Neuland Laboratories Limited (NEULANDLAB) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Limited leads NEULANDLAB vs SUNPHARMA on 9 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability22
  • Growth20
  • Size & financial health04
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

SUNPHARMA takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

70.97
P/E ratio
36.79
16.30
P/B ratio
5.35
0.14%
Dividend yield
0.86%
₹283.71
EPS
₹47.80

Profitability

Even

How efficiently each company turns capital and sales into profit. Higher is better.

19.42%
Return on equity
13.74%
23.57%
Return on capital
17.46%
28.40%
EBITDA margin
30.33%
17.99%
Net margin
19.69%

Growth

NEULANDLAB takes 2/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

19.31%
Revenue CAGR (3Y)
10.03%
30.57%
Profit CAGR (3Y)
10.57%

Size & financial health

SUNPHARMA takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹25,275 Cr
Market cap
₹4.22L Cr
₹2,023 Cr
Revenue
₹58,462 Cr
₹364 Cr
Net profit
₹11,509 Cr
0.16
Debt / equity
0.06
Neuland Laboratories Limited
  • + ["Company has delivered good profit growth of 35.2% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 22.1%", "Company has delivered good sales growth of 16.6% CAGR over last 5 years"]
  • − ["Stock is trading at 13.48 times its book value"]
Sun Pharmaceutical Industries Limited
  • + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
  • − ["Stock is trading at 5.05 times its book value"]
Neuland Laboratories Limited full analysis Sun Pharmaceutical Industries Limited full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.